Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Las Vegas Sands Corp. — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Las Vegas Sands Corp. trades at $37.07 (market cap $23.99B). The key difference: Las Vegas Sands Corp. is far larger — about 2.8× Hinge Health Inc. Class A Common Stock's market cap, and Las Vegas Sands Corp. pays a 3.24% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Las Vegas Sands Corp. for 73 Days on average.
| HNGE | LVS | |
|---|---|---|
Market Cap | $8.48B | $23.99B |
Volume | 879,799 | 5,076,550 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $69.49 |
52-Week Low | $31.17 | $35.81 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $8.10B | $35.88B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
LVS trades at $37.02, up 2.41% today, but faces bearish technical signals with strong selling pressure on moving averages. The company shows solid fundamentals with revenue growth from $13.02B in 2025 to projected $13.7B in 2026, net margins around 12.5%, and attractive valuation with P/E of 14.36. Recent earnings show mixed results with Q2 2026 missing expectations after two consecutive beats. Analysts maintain strong buy consensus with $58.89 price target representing 59% upside potential.
LVS presents compelling value with strong analyst support and reasonable valuations, though technical weakness and high debt levels pose near-term risks. The company's consistent revenue growth and Macao recovery provide upside catalysts, but investors should monitor debt management and gaming regulatory environment. The significant gap between current price and analyst targets suggests substantial potential reward for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
